Aviva’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.4M Sell
96,148
-1,136
-1% -$223K 0.03% 415
2026
Q1
$19.1M Buy
97,284
+2,427
+3% +$472K 0.03% 409
2025
Q4
$16.5M Buy
94,857
+1,852
+2% +$337K 0.03% 440
2025
Q3
$17.7M Buy
93,005
+3,589
+4% +$637K 0.03% 414
2025
Q2
$16.1M Buy
89,416
+5,562
+7% +$966K 0.03% 416
2025
Q1
$14.2M Buy
83,854
+12,704
+18% +$2.09M 0.03% 397
2024
Q4
$10.7M Sell
71,150
-140,165
-66% -$21.8M 0.03% 431
2024
Q3
$32.8M Buy
211,315
+9,340
+5% +$1.39M 0.09% 273
2024
Q2
$27.6M Buy
201,975
+46,110
+30% +$6.31M 0.08% 294
2024
Q1
$20.7M Buy
155,865
+46,371
+42% +$6.02M 0.07% 326
2023
Q4
$15.1M Sell
109,494
-61,160
-36% -$8.04M 0.05% 382
2023
Q3
$20.8M Sell
170,654
-4,653
-3% -$620K 0.09% 297
2023
Q2
$24.6M Sell
175,307
-127,997
-42% -$17.6M 0.1% 242
2023
Q1
$42.9M Buy
303,304
+114,548
+61% +$16.4M 0.19% 118
2022
Q4
$29.5M Buy
188,756
+57,972
+44% +$8.33M 0.15% 172
2022
Q3
$16M Buy
130,784
+17,002
+15% +$2.24M 0.09% 309
2022
Q2
$15.1M Buy
113,782
+45,714
+67% +$6.23M 0.08% 343
2022
Q1
$9.32M Buy
68,068
+12,298
+22% +$1.71M 0.05% 447
2021
Q4
$9.65M Buy
55,770
+7,649
+16% +$1.16M 0.04% 404
2021
Q3
$6.99M Buy
48,121
+4,500
+10% +$658K 0.03% 480
2021
Q2
$5.76M Sell
43,621
-1,371
-3% -$180K 0.03% 551
2021
Q1
$5.77M Buy
44,992
+1,011
+2% +$125K 0.03% 491
2020
Q4
$5.24M Buy
43,981
+648
+1% +$79K 0.03% 489
2020
Q3
$4.96M Sell
43,333
-1,030
-2% -$122K 0.03% 451
2020
Q2
$5.06M Sell
44,363
-46,181
-51% -$4.9M 0.03% 425
2020
Q1
$7.27M Buy
90,544
+25,590
+39% +$2.65M 0.05% 322
2019
Q4
$6.94M Buy
64,954
+17,728
+38% +$1.85M 0.04% 372
2019
Q3
$5.05M Sell
47,226
-2,944
-6% -$302K 0.03% 420
2019
Q2
$5.11M Sell
50,170
-1,096
-2% -$105K 0.04% 440
2019
Q1
$4.61M Buy
51,266
+406
+0.8% +$35.2K 0.03% 481
2018
Q4
$4.24M Sell
50,860
-27,002
-35% -$2.53M 0.03% 476
2018
Q3
$8.4M Sell
77,862
-2,980
-4% -$327K 0.05% 372
2018
Q2
$8.89M Sell
80,842
-838
-1% -$87.3K 0.05% 339
2018
Q1
$8.19M Sell
81,680
-7,370
-8% -$755K 0.05% 354
2017
Q4
$8.77M Sell
89,050
-10,843
-11% -$1.03M 0.05% 366
2017
Q3
$9.35M Buy
99,893
+640
+0.6% +$67.9K 0.05% 365
2017
Q2
$11M Buy
99,253
+460
+0.5% +$48.6K 0.06% 330
2017
Q1
$9.7M Sell
98,793
-4,904
-5% -$467K 0.06% 346
2016
Q4
$9.53M Buy
103,697
+4,830
+5% +$416K 0.06% 346
2016
Q3
$8.37M Buy
98,867
+12,496
+14% +$1.05M 0.05% 391
2016
Q2
$7.03M Sell
86,371
-72,416
-46% -$5.51M 0.05% 405
2016
Q1
$11.3M Buy
158,787
+3,119
+2% +$209K 0.08% 260
2015
Q4
$11.1M Buy
155,668
+84,693
+119% +$5.69M 0.08% 265
2015
Q3
$4.36M Sell
70,975
-1,886
-3% -$132K 0.04% 516
2015
Q2
$5.28M Sell
72,861
-5,040
-6% -$372K 0.04% 487
2015
Q1
$5.99M Buy
77,901
+18,347
+31% +$1.31M 0.04% 483
2014
Q4
$3.99M Sell
59,554
-110
-0.2% -$6.94K 0.03% 543
2014
Q3
$3.62M Sell
59,664
-540
-0.9% -$33.3K 0.03% 585
2014
Q2
$3.53M Sell
60,204
-380
-0.6% -$22.3K 0.03% 595
2014
Q1
$3.51M Sell
60,584
-60
-0.1% -$3.22K 0.03% 571
2013
Q4
$3.25M Buy
60,644
+347
+0.6% +$20.6K 0.03% 585
2013
Q3
$3.73M Buy
60,297
+14,166
+31% +$848K 0.03% 510
2013
Q2
$2.8M Buy
+46,131
New +$2.75M 0.03% 508

Other funds holding DGX

Aviva's DGX Position: Q2 2026 in Review

Aviva reduced its Quest Diagnostics (DGX) stake by 1.2% in Q2 2026, selling an estimated $223K and leaving 96,148 shares worth $20.4M. The position accounts for 0.03% of the portfolio, ranked #415.

Aviva first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $42.9M in Q1 2023. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Aviva held 96,148 shares of Quest Diagnostics worth $20.4M as of Q2 2026.
  • Aviva sold 1,136 Quest Diagnostics shares in Q2 2026, an estimated $223K.
  • Quest Diagnostics made up 0.03% of Aviva's portfolio in Q2 2026, its #415 holding.
  • Aviva first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Quest Diagnostics position peaked at $42.9M in Q1 2023.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.